Anaplastic thyroid carcinoma: Treatment in the age of molecular targeted therapy

Journal of Oncology Practice

Volumn 12, Issue 6, 2016, Pages 511-518

  Cabanillas, Maria E ^a   Zafereo, Mark ^a   Gunn, G Brandon ^a   Ferrarotto, Renata ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DIFFERENTIAL DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HEALTH CARE QUALITY; HUMAN; LOCAL THERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; REVIEW; SURGICAL PATIENT; TERTIARY CARE CENTER; THYROID CARCINOMA; TRACHEOTOMY; TUMOR GROWTH; GENETIC SCREENING; GENETICS; PATHOLOGY; THYROID CARCINOMA, ANAPLASTIC;

GENETIC TESTING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; THYROID CARCINOMA, ANAPLASTIC;

EID: 84974574975     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.012013     Document Type: Review

References (42)

1. Smallridge RC, Copland JA: Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22:486-497, 2010
2. Smallridge RC, Ain KB, Asa SL, et al: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104-1139, 2012
3. ForbesSA, Beare D,Gunasekaran P, et al:COSMIC: Exploring theworld's knowledgeof somatic mutations in human cancer. Nucleic Acids Res 43:D805-D811, 2015
4. Kunstman JW, Juhlin CC, Goh G, et al: Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. HumMol Genet 24:2318-2329, 2015
5. Landa I, Ibrahimpasic T, Boucai L, et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-1066, 2016
6. Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676-690, 2014
7. Brose MS, Cabanillas ME, Cohen EE, et al: An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation and resistant to radioactive iodine. Presented at Proc European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013
8. Dadu R, Shah K, Busaidy NL, et al: Efficacy and tolerability of vemurafenib in patientswith BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100:E77-E81, 2014
9. Murugan AK, Xing M: Anaplastic thyroid cancers harbor novel oncogenic mutationsof the ALK gene. Cancer Res 71:4403-4411, 2011
10. Wagle N, Grabiner BC, Van Allen EM, et al: Response and acquired resistance toeverolimus in anaplastic thyroid cancer. N Engl J Med 371:1426-1433, 2014
11. Godbert Y, Henriques de Figueiredo B, Bonichon F, et al: Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J Clin Oncol 33:e84-e87, 2015
12. Cabanillas M, Williams MD, Gunn B, et al: Facilitating anaplastic thyroid cancer specialized treatment (FAST): A model for increasing enrollment to anaplastic thyroid cancer (ATC) clinical trials. Thyroid 25, 2015 (suppl 1; abstr 678)
13. Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual (ed 6).New York, NY, Springer, 2002
14. Bhatia A, Rao A, Ang KK, et al: Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 32:829-836, 2010
15. De Crevoisier R, Baudin E, Bachelot A, et al: Combined treatment of anaplasticthyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137-1143, 2004
16. Tennvall J, Lundell G, Wahlberg P, et al: Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848-1853, 2002
17. Busnardo B, Daniele O, Pelizzo MR, et al: A multimodality therapeutic approachin anaplastic thyroid carcinoma: Study on 39 patients. J Endocrinol Invest 23: 755-761, 2000
18. Higashiyama T, Ito Y, Hirokawa M, et al: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20: 7-14, 2010
19. Uruno T, Ogimi Y, Saito F, et al: Proposal of a new staging system and treatment algorithm for anaplastic thyroid cancer by induction weekly paclitaxel. Thyroid 25, 2015 (suppl 1; abstr 645)
20. Dean AP, Yeong Hong Goh R, Smith P: Anaplastic thyroid cancer: A report of 5 consecutive cases treated successfully with nab-paclitaxel. J Clin Oncol 33, 2015 (abstr e17095)
21. Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al: Multimodality treatment foranaplastic thyroid carcinoma-Treatment outcome in 75 patients. Radiother Oncol 92:100-104, 2009
22. Brignardello E, Gallo M, Baldi I, et al: Anaplastic thyroid carcinoma: Clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156:425-430, 2007
23. Haigh PI, Ituarte PH, Wu HS, et al: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335-2342, 2001
24. Troch M, Koperek O, Scheuba C, et al: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 95:E54-E57, 2010
25. Kumar A, Prasongsook N, Kasperbauer J, et al: Outcomes in response to aggressive multi-modal therapy in anaplastic thyroid cancer: The Mayo Clinic experience. Thyroid 25, 2015; (suppl 1; abstr 72)
26. Ain KB, Egorin MJ, DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Thyroid 10:587-594, 2000
27. Kawada K, Kitagawa K, Kamei S, et al: The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40:596-599, 2010
28. Shimaoka K, Schoenfeld DA, DeWys WD, et al: A randomized trial of doxorubicinversus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985
29. Sosa JA, Elisei R, Jarzab B, et al: Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24:232-240, 2014
30. Cabanillas ME, Dadu R, Waguespack SG: Response to dabrafenib and trametinibin a patient with BRAF V600E-mutated anaplastic thyroid cancer. Thyroid 25, 2015 (suppl 1; abstr 226)
31. Rosove MH, Peddi PF, Glaspy JA: BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684-685, 2013
32. Lorch JH, Busaidy N, Ruan DT, et al: A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol 31, 2013 (abstr 6023)
33. Onoda N, Ito Y, Ito K, et al: Phase II clinical trial of sorafenib in Japanese patients with anaplastic thyroid carcinoma (ATC) and locally advanced or metastatic medullary thyroid carcinoma (MTC). Thyroid 25, 2015 (suppl 1; abstr 292)
34. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
35. Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009
36. Bible KC, Suman VJ, Menefee ME, et al: A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97:3179-3184, 2012
37. Takahashi S, Tahara M, Kiyota N, et al: Phase II study of lenvatinib, a multitargeted tyrosine kinase inhibitor, in patients with all histologic subtypes of advanced thyroid cancer (differentiated,medullary, and anaplastic). Ann Oncol 24:iv340-iv356, 2013 (suppl 4)
38. Gramza AW, Balasubramaniam S, Fojo AT, et al: Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: Phase 1 results. J Clin Oncol 31, 2013 (abstr 6074)
39. Smallridge RC, Copland JA, Brose MS, et al: Efatutazone, an oral PPAR-g agonist, in combination with paclitaxel in anaplastic thyroid cancer: Results of a multicenter phase 1 trial. J Clin Endocrinol Metab 98:2392-2400, 2013
40. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
41. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014
42. Dadu R, Rodriguez Canales J, Wistuba I, et al: Targeting immune system in anaplastic thyroid cancer (ATC): A potential treatment approach. Thyroid 25, 2015 (suppl 1; abstr 749)